Key result
Vigorous physical activity improves functional capacity without increasing adverse events in most low-risk hypertrophic cardiomyopathy patients.
Why the study?
Does physical activity and individualized exercise prescription improve functional capacity and cardiovascular outcomes without increasing adverse events in patients with hypertrophic cardiomyopathy?
Does physical activity and individualized exercise prescription improve functional capacity and cardiovascular outcomes without increasing adverse events in patients with hypertrophic cardiomyopathy?
This review highlights a paradigm shift away from universal exercise restriction in hypertrophic cardiomyopathy toward individualized exercise prescriptions supported by shared decision-making and risk stratification.
Answers are grounded in this paper and cite their sources.
Supports individualized exercise in low-risk HCM; leaves open prospective trials before practice change.
This article outlines the evolving evidence and guidelines surrounding exercise in hypertrophic cardiomyopathy (HCM), challenging the traditional paradigm of universal restriction. It highlights that most patients with HCM can safely engage in physical activity (PA) and improve cardiovascular outcomes. Recent evidence demonstrates that vigorous PA improves functional capacity and does not increase adverse events in most low-risk HCM patients. Contemporary guidelines advocate for individualized exercise recommendations based on comprehensive risk stratification and shared decision-making. A clinical framework is proposed to support tailored exercise prescriptions and shared decision-making.
No takes yet. Share an insight, caveat, or question.
Hyun-Jung Lee (2026) conducted a review in Hypertrophic cardiomyopathy (HCM). Physical activity and tailored exercise prescriptions vs. Universal exercise restriction was evaluated on Cardiovascular outcomes, functional capacity, and adverse events. Vigorous physical activity improves functional capacity without increasing adverse events in most low-risk hypertrophic cardiomyopathy patients.
Synapse has enriched 10 related papers. Consider them for comparative context: